Combining Comparative Proteomics and Molecular Genetics Uncovers Regulators of Synaptic and Axonal Stability and Degeneration In Vivo

Citation for published version:
https://doi.org/10.1371/journal.pgen.1002936

Digital Object Identifier (DOI):
10.1371/journal.pgen.1002936

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS Genetics

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Combining Comparative Proteomics and Molecular Genetics Uncovers Regulators of Synaptic and Axonal Stability and Degeneration In Vivo

Thomas M. Wishart1,2,3, Timothy M. Rooney4, Douglas J. Lamont5, Ann K. Wright1,2, A. Jennifer Morton6, Mandy Jackson1,2, Marc R. Freeman4, Thomas H. Gillingwater1,2*

1 Centre for Integrative Physiology, University of Edinburgh, Edinburgh, United Kingdom, 2Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom, 3 Division of Neurobiology, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, United Kingdom, 4 Department of Neurobiology, Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 5 FingerPrints Proteomics Facility, College of Life Sciences, University of Dundee, Dundee, United Kingdom, 6 Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom

Abstract

Degeneration of synaptic and axonal compartments of neurons is an early event contributing to the pathogenesis of many neurodegenerative diseases, but the underlying molecular mechanisms remain unclear. Here, we demonstrate the effectiveness of a novel “top-down” approach for identifying proteins and functional pathways regulating neurodegeneration in distal compartments of neurons. A series of comparative quantitative proteomic screens on synapse-enriched fractions isolated from the mouse brain following injury identified dynamic perturbations occurring within the proteome during both initiation and onset phases of degeneration. In silico analyses highlighted significant clustering of proteins contributing to functional pathways regulating synaptic transmission and neurite development. Molecular markers of degeneration were conserved in injury and disease, with comparable responses observed in synapse-enriched fractions isolated from mouse models of Huntington’s disease (HD) and spinocerebellar ataxia type 5. An initial screen targeting thirteen degeneration-associated proteins using mutant Drosophila lines revealed six potential regulators of synaptic and axonal degeneration in vivo. Mutations in CALB2, ROCK2, DNAJC5/CSP, and HIBCH partially delayed injury-induced neurodegeneration. Conversely, mutations in DNAJC6 and ALDHA1 led to spontaneous degeneration of distal axons and synapses. A more detailed genetic analysis of DNAJC5/CSP mutants confirmed that loss of DNAJC5/CSP was neuroprotective, robustly delaying degeneration in axonal and synaptic compartments. Our study has identified conserved molecular responses occurring within synapse-enriched fractions of the mouse brain during the early stages of neurodegeneration, focused on functional networks modulating synaptic transmission and incorporating molecular chaperones, cytoskeletal modifiers, and calcium-binding proteins. We propose that the proteins and functional pathways identified in the current study represent attractive targets for developing therapeutics aimed at modulating synaptic and axonal stability and neurodegeneration in vivo.


Editor: Andrew D. Chisholm, University of California San Diego, United States of America

Received December 20, 2011; Accepted July 18, 2012; Published August 30, 2012

Copyright: © 2012 Wishart et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the Wellcome Trust (THG, MRF), Department of Defense BCRP (TMR), and NIH RO1 NS059991 (MRF). TMW is currently supported by Roslin Institute Strategic Grant funding from the BBSRC. MRF is an Early Career Scientist of the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

E-mail: T.Gillingwater@ed.ac.uk

Introduction

Synaptic and axonal compartments of neurons are exceptionally vulnerable to a wide array of neurodegenerative stimuli, ranging from physical trauma through to genetic disease [1]. As a result, the important role that synapses and axons play in the initiation and progression of a wide range of neurodegenerative conditions is becoming increasingly well documented. For example, published studies have highlighted an important role for synaptic malfunction and degeneration in pre-clinical and early-symptomatic stages of Alzheimer’s disease [2], Parkinson’s disease [3], Huntington’s disease (HD) [4], spinocerebellar ataxia [5], prion diseases [6], lysosomal storage disorders [7] and motor neuron diseases [8,9]. In many such conditions, synaptic and axonal pathology is instigated in advance of pathological changes in other regions of the neuron (e.g. the cell soma). Thus, neuroprotective strategies directly targeting synapses and axons are likely to provide important options for treating neurodegenerative disorders in human patients [1,10,11].

Despite an increasing awareness of the scientific and clinical importance of synaptic and axonal degeneration, little is known about why distal compartments of neurons are particularly vulnerable. Furthermore, our understanding of molecular and genetic mechanisms regulating neurodegeneration remains in its infancy. Of the many proteins present in synapses and distal axons, only a few have been shown to be capable of directly modulating neurodegeneration. One of the most extensively characterised, the chimeric Wallerian degeneration slow (WldS) protein [12–14], is
confirmed that loss of this synaptic protein was neuroprotective, protein kinase 2). A more robust genetic analysis of DNAJC5/CSP hydrolase) and ROCK2 (Rho-associated, coiled-coil containing subfamily B, member 6), HIBCH (3-hydroxyisobutyryl-CoA nase), CALB2 (calbindin2), DNAJC5/CSP (DnaJ (Hsp40) homo- 

In diseases affecting the nervous system, such as Alzheimer’s disease and motor neuron disease, the breakdown of synaptic connections between neurons is a critical early event, contributing to disease onset and progression. However, we still know very little about the molecular machinery present in synaptic and axonal compartments of neurons that regulate their stability and cause breakdown during neurodegeneration. In this study we examined the protein composition of healthy and degenerating synapse-enriched fractions isolated from the brains of mice in order to identify early molecular changes occurring during neurodegeneration. We identified a range of proteins and cellular pathways that were modulated in synapse-enriched fractions during the early phases of degeneration, many of which were already known to regulate synaptic function. Similar molecular alterations were found in synapse-enriched fractions prepared from mouse models of Huntington’s disease (HD) and spinocerebellar ataxia type 5. Data from these proteomic studies were then used to design experiments in Drosophila, in which we found that at least six of the individual proteins modified in degenerating synapses from mice were capable of independently regulating neuronal stability and degeneration in vivo. Designing novel therapeutics to target these proteins and pathways may help to delay or prevent neurodegeneration across a range of diseases.

encoded by a novel chimeric gene formed by a spontaneous mutation event in laboratory mice. It is not, therefore, endogeneously expressed in other species, including humans. Examples of endogenous proteins capable of modulating synapse and distal axon degeneration in vivo are relatively rare, including cysteine string protein alpha (also known as DNAJC5) [15] and some synucleins [16,17] (for review see [11]). There is, therefore, a need to identify other proteins and pathways capable of modulating synaptic and axonal stability and degeneration in vivo. However, this is likely to require the development of integrated experimental approaches capable of identifying and characterizing molecular responses to degeneration in distal compartments of neurons.

Here, we report on the development of a novel ‘top-down’ approach for identifying proteins and functional pathways regulating neurodegeneration in distal compartments of neurons in vivo. We combined sequential comparative proteomic screens on synapse-enriched fractions isolated from the mouse brain undergoing injury-induced degeneration with molecular genetic dissection of mechanisms underlying degeneration in Drosophila. We show that synaptic and axonal degeneration is associated with dynamic perturbations to the proteome, impacting on molecular pathways involved with synaptic transmission and neurite development. Experiments on two mouse models of neurodegenerative disease (Huntington’s disease and spinocerebellar ataxia type 5) showed that molecular pathways underlying distal neuron degeneration were conserved from injury to disease. Genetic manipulation of 13 synaptic proteins using mutant Drosophila lines led to the identification of 6 potential regulators of axonal and synaptic degeneration in vivo. ALDH1A1 (Aldehyde dehydrogenase), CALB2 (calbindin2), DNAJC5/CSP (DnaJ) (Hsp40) homolog, subfamily C, member 5), DNAJC6 (DnaJ) (Hsp40) homolog, subfamily B, member 6), HIBCH (3-hydroxyisobutyryl-CoA hydrolase) and ROCK2 (Rho-associated, coiled-coil containing protein kinase 2). A more robust genetic analysis of DNAJC5/CSP confirmed that loss of this synaptic protein was neuroprotective, robustly delaying degeneration in axonal and synaptic compartments of neurons in vivo. We conclude that conserved molecular responses are instigated locally within distal compartments of neurons during the early stages of neurodegeneration. Such responses are focused around networks of proteins modulating synaptic transmission, incorporating molecular chaperones, cytoskeletal modifiers, and calcium binding proteins.

Results

Proteomic identification of molecular responses to degeneration in synapse-enriched fractions of the mouse brain

To uncover molecular pathways activated in synapses and axons during the early stages of neurodegeneration we initially wanted to obtain a global overview of protein expression changes occurring locally within distal neuronal compartments undergoing degeneration in response to a defined stimulus. We therefore performed a series of comparative, unbiased proteomic screens on synapse-enriched fractions biochemically isolated from the mouse brain (see Methods and Figure 1A) [18]. The relative absence of nuclear proteins (BRCA2) and glial cell proteins (MBP), alongside robust levels of synaptic proteins synaptophysin and synapsin 1 (Figure 1A), confirmed the enrichment of synaptic material in these preparations. However, it should be noted that low-level contamination originating from other cell types and/or non-synaptic fractions is likely to be present in these preparations.

Synaptic and distal axon degeneration was induced using an in vivo cortical lesion model that injures cell bodies and proximal axons giving rise to corticostriatal projections. In this model unilateral ablation of one cortical hemisphere down to the level of the corpus callosum reliably triggers axonal and synaptic degeneration in the underlying ipsilateral striatum [14,19]. Morphological evidence for axonal and synaptic degeneration is not observed until 48 hours following injury in wild-type mice (C57Bl/6) [14,19], revealing the presence of a ~24–48 hour lag period preceding the physical onset of degeneration. We therefore generated synapse-enriched fractions preparations from the striatum of wild-type mice at 3 time points (N = 6 mice per time point); prior to injury (0 hrs), providing a baseline for protein detection and expression; 24 hours following injury (24 hrs) to identify immediate early responses triggered during the initiation of degeneration; and 48 hours following injury (48 hrs), correlating with the onset of synaptic breakdown. In order to increase stringency in reporting, a minimum cut-off threshold of 20% change versus uninjured controls was used to indicate a protein with modified expression levels. iTRAQ (Isobaric Tag for Relative and Absolute Quantitation) proteomic analyses identified a total of 178 putative proteins (from a pool of 36,957 peptide sequences) with expression levels modified by more than 20% at either 24 h or 48 hr after injury compared to uninjured (0 hrs) controls. Of these, 112 putative proteins showed expression changes of greater than 20% maintained at 48 hrs following injury (Table S1). Bioinformatics analysis of the 178 putative proteins using IPA software revealed that >87% of the proteins were cytoplasmic or membrane bound, consistent with them being synaptic proteins, rather than arising as a result of contamination from nuclear compartments.

Modifications to the proteome of synapse-enriched fractions revealed in our initial analyses are unlikely to solely represent responses directly associated with degeneration, as the cortical lesion injury used generated systemic responses in corticostriatal networks that could conceivably effect the molecular composition of the tissue (e.g. in response to modified patterns of activity). In
order to improve our dataset, leaving only molecular responses directly associated with active processes of degeneration, we refined our analysis by undertaking a subsequent comparison with proteomic data obtained from synapse-enriched fractions in mice genetically protected from neurodegeneration by the \textit{WldS} gene. We have previously demonstrated that both axonal and synaptic degeneration in the striatum are absent for at least 6 days after a cortical lesion in \textit{WldS} mice [14,19]. We therefore reasoned that any alterations to the proteome observed in \textit{WldS} mice at either 24 hrs or 48 hrs after injury were more likely to represent systemic responses to the lesion injury itself rather than changes directly related to the process of synaptic and axonal degeneration. iTRAQ proteomic analyses were therefore performed on tissue from \textit{WldS} mice using the same protocol adopted for our initial experiments on wild-type animals. Through subtracting candidates identified in synapse-enriched fractions from both wild-type and \textit{WldS} mice following injury (Table S2; validated using western blotting at 72 hrs after injury, Figure 1B), we refined our dataset to include only those putative proteins with modified expression in synapse-enriched fractions undergoing degeneration (Figure 1C–1D). This approach removed a total of 19 candidates from the dataset, resulting in a refined profile comprised of 93 putative proteins.

Given that we planned to use data generated by our proteomics analysis to directly guide subsequent molecular genetic experiments in \textit{Drosophila} (see below), we wanted to exclude any of the 93 putative proteins identified for which we could not be certain of their identity based on the peptide sequences reported from the proteomics analysis. We therefore excluded all putative proteins identified only by 1 unique peptide that we could not subsequently validate by western blotting. Examples of validation western blots for one up-regulated (\textit{UBR4}) and one down-regulated (\textit{ABLI1}) protein are shown in Figure 2A. This generated a final refined list of 47 unique proteins with robustly modified expression in synapse-enriched fractions 48 hrs after injury (Table S3; Figure 2B). These 47 proteins were therefore considered to represent robust molecular perturbations occurring in synapse-enriched fractions during the initiation and onset phases of neurodegeneration \textit{in vivo}.

### A complex temporal profile of protein expression changes during neurodegeneration

Expression mapping of all 47 proteins identified as having modified expression levels in degenerating synapse-enriched fractions allowed them to be grouped according to the temporal dynamics of their responses, as well as magnitude of expression change (Figure 2B). Given that synaptic degeneration was absent in the striatum 24 hrs after cortical lesion, but was widespread at 48 hrs after lesion [14, 19], we reasoned that individual proteins responding within 24 hrs of lesion were more likely to represent immediate-early responders and initiators of the degeneration process. By contrast, we reasoned that individual proteins whose expression levels were found to be altered only at 48 hrs after the lesion were more likely to represent effector pathways involved with the onset of degeneration.

Diverse temporal patterns of expression changes were observed across the 47 proteins examined, suggesting that our analyses had detected proteins contributing both to early initiating phases and onset phases of degeneration (Figure 3). Of the 47 synaptic proteins identified 24 responded within 24 hrs of injury. Of these, 14 remained stable at 48 hrs whereas 10 showed additional incremental changes by 48 hrs. The other 23 proteins were unchanged at 24 hrs, responding only at 48 hrs after injury (Figure 3).

#### In silico analysis revealed significant functional clustering of proteins

Next, we wanted to establish whether the profile of individual protein alterations identified in degenerating synapse-enriched fractions represented perturbations of specific functional pathways. We performed an \textit{in silico} systems level analysis on the proteomics...
data using Ingenuity Pathway Analysis (IPA) software. This analysis identifies statistically significant functional clustering of proteins, based on known protein interactions and biological functions reported in the published literature [18]. Functional networks identified by the IPA software are statistically ranked according to a score calculated via a right-tailed Fischer’s exact test, taking into account the number of original input proteins and the size of the network generated as a result. Only networks comprised of 3 or more identified proteins and reported with a \( P \) value of \( <0.05 \) were considered as being significant. These experiments revealed that the 47 identified proteins were functionally clustered into a relatively small group of networks (Table S4), focused principally around pathways regulating synaptic function (including synaptic transmission, exocytosis, transport of vesicles and formation of vesicles) and neurite development (including guidance of axons, formation of filaments, development of neurites and biogenesis of the cytoskeleton).

The \textit{in silico} analysis also highlighted many proteins previously implicated in molecular pathways underlying neurological conditions (Table S4). Interestingly, these included neurodegenerative conditions where synapses and axons are known to be primary pathological targets (e.g. Alzheimer’s disease, Parkinson’s disease and HD; see introduction).

Molecular pathways underlying synapse pathology are conserved from injury to disease

Next, we wanted to establish whether molecular pathways modified as a result of injury-induced degeneration were similarly conserved from injury to disease.

Figure 2. Temporal expression profiling identifies molecular changes occurring in synapse-enriched fractions from the striatum undergoing degeneration. A. Representative bands from fluorescent western blots for one up-regulated protein (Ablim1) and one down-regulated protein (Ubr4) in degenerating synapse-enriched fractions, validating expression changes observed in proteomic experiments. Tubulin is shown as a loading control. B. Graphical representation of protein expression changes for all 47 proteins modified in degenerating synapse-enriched fractions (see Table 1), illustrating global trends in the magnitude and scope of alterations identified.

doi:10.1371/journal.pgen.1002936.g002

Figure 3. Temporal expression profiling for individual proteins identified in synapse-enriched fractions undergoing degeneration. Temporal profiles of protein expression changes in degenerating synapse-enriched fractions were grouped into 3 distinct categories: proteins with expression changes \( >20\% \) by 24 hours, with further progressive alterations by 48 hours (A); proteins up or down regulated \( >20\% \) by 24 hours following injury but with no subsequent increase/decrease (B); and proteins not changed at 24 hours but up or down regulated \( >20\% \) at 48 hours following injury (C). Proteins responding within 24 hrs of lesion were considered to represent immediate-early responders and initiators of the degeneration process, whereas proteins whose expression levels were found to be altered only at 48 hrs after the lesion were considered to represent effector pathways involved with the onset of degeneration.

doi:10.1371/journal.pgen.1002936.g003
identified following injury (see Table 1). NS = not significant; *P
Bars to the right of the dotted line show levels of proteins previously
line show levels of control proteins (including Huntingtin [HTT]). Bars to the right of the
dotted line show levels of proteins previously identified following injury
(see Table 1). NS = not significant; *P<0.05; **P<0.01; Mann-Whitney test. D. Representative bands from quantita-

deviation of synaptic alterations in neurodegenerative diseases resulting from genetic
mutations. We therefore selected 11 proteins from our injury
proteomics data where reliable antibodies were available for use in
quantitative fluorescent western blotting experiments (ABLIM1, SPBTN, CCT7/TCP1, CFL1, CNP, DNAJC5/CSP, INPP4A, NFASC, ROCK2, SIRT2 and UBR4). These included candidates
from the top five cellular process categories identified in our
functional clustering analysis (see Table S4). We quantified
expression levels in synapse-enriched fractions isolated from two
distinct mouse models of neurodegenerative disease at early-
symptomatic time-points: a genetic disease model with synaptic
degeneration (the R6/2 mouse model of HD) and a model of
spino-cerebellar ataxia type 5 with synaptic dysfunction/dysregulation (βIII-spectrin knockout mouse).

The pathophysiology of HD involves aggregation of mutated
huntingtin (Htt) protein, transcriptional dysregulation, altered
energy metabolism, excitotoxicity, impaired axonal transport
and synaptic pathology [20]. The R6/2 mouse model of HD exhibits a progressive and fatal neurological phenotype, with synaptic
alterations notable in the striatum [4]. Protein expression levels
were analysed in synapse-enriched fractions generated from the
striatum of R6/2 mice carrying a CAG repeat of 259–266 at 9–10
weeks of age (representing early-symptomatic stages of the disease).

11 of the 11 proteins examined, showed significant changes in
expression levels in fractions prepared from R6/2 mice (Figure 4A
and 4B).

The βIII-spectrin knockout mouse models many of the human
aspects of spinocerebellar ataxia type 5, including; synaptic
dysfunction, postural abnormalities, progressive loss of motor
coordination, and cerebellar degeneration [5]. Protein expression
levels were analysed in synapse-enriched fractions generated from the
cerebellum of βIII-spectrin knockout mice at 12 weeks of age
(representing early-symptomatic stages of the disease [5]). Of the
10 proteins examined, showed significant changes in expression levels in βIII-spectrin knockout mice (Figure 4C and 4D).

Comparisons of protein expression data obtained from the
cortical lesion model, R6/2 model and βIII-spectrin knockout
revealed that 9 of the examined proteins showed expression changes occurring in the same direction across all three models
(Figure 4E). Although the magnitude of identified expression
changes were not always identical between models (and often were
variable between individual mice), this likely represents the
differing extent and nature of synaptic pathology observed
between the three models at the time-points examined [4,5,14].

Identification of individual proteins capable of
independently regulating synaptic and distal axon
degeneration in vivo

Although we had obtained a clear understanding of conserved
molecular alterations occurring in synapse-enriched fractions
undergoing neurodegeneration, it remained unclear whether or

Figure 4. Molecular pathways underlying degeneration in
synapse-enriched fractions are conserved across diverse
neurodegenerative conditions. A. Bar chart (mean±SEM) showing
quantitative fluorescent western blot data for protein expression levels in
synapse-enriched fractions from the striatum generated from the R6/2
transgenic mouse model of HD compared to wild-type controls (N=3
mice per genotype). Bars to the left of the dotted line show levels of
control proteins (including Huntingtin [HTT]). Bars to the right of the
dotted line show levels of proteins previously identified following injury
(see Table 1). NS = not significant; *P<0.05; **P<0.01; Mann-Whitney test. B. Representative bands from quantitative fluorescent western blot experiments on synapse-enriched fractions from wild-type (WT) and βIII-spectrin knockout (KO) mice. E. Comparison of protein expression changes in synapse-enriched fractions from the
injury model (summarized from the proteomics data), R6/2 mice and
βIII-spectrin KO mice. Red boxes indicate mean expression decreased
>10%, green boxes indicate mean expression increased >10%, grey
boxes indicate changes <10%. Up = significantly upregulated com-
pared to controls; Down = significantly downregulated compared to
controls; NS = not significantly changed compared to controls.
doi:10.1371/journal.pgen.1002936.g004
Representative confocal micrographs showing three distinct phenotypic profiles observed in injured and uninjured ORN axons and synapses 7 days after unilateral (right hand side of image) antennal ablation. The top panel shows intact healthy axons and synapses on the uninjured side and complete axonal degeneration (indicated by absence of GFP labeled profiles) on the injured side (example from an NFASC mutant). The middle panel shows delayed axo-synaptic degeneration on the injured side, as indicated by the retention of GFP-labeled axons and synapses (white arrows; example from a DNAJC6 mutant). The bottom panel shows spontaneous (i.e. not injury-induced) axo-synaptic degeneration in the uninjured axons and synapses, indicated by reduction and fragmentation of GFP labeled axons and synapses (white arrows; example from a DNAJC6 mutant). C. Bar chart (mean ± SEM) showing index scores (see methods) for spontaneous degeneration (S; grey bars) and delayed degeneration (D; black bars) in 7 mutant Drosophila lines. OGDH is shown as an example of a mutant line with no overt phenotype. DNAJC6 and ALDH1A1 mutants revealed evidence for spontaneous degeneration in the absence of any injury stimulus. DNAJC5, CALB2, ROCK2 and HIBCH mutants revealed evidence for delayed degeneration following antennal ablation.

doi:10.1371/journal.pgen.1002936.g005

Figure 5. Overview of putative axo-synaptic degeneration phenotypes observed in Drosophila neurodegeneration screens. A. Representative confocal micrograph showing the morphology of the intact Drosophila olfactory receptor neuron (ORN) system, with axons and synaptic fields labeled with GFP in the UAS-mCD8::GFP;OR22a-Gal4/+ background. Axons enter the antennal lobe laterally and project medially across the lobe to reach their target glomerulus, where synapses are located (see reference [21]). B. not any of the proteins and pathways identified were capable of actively modulating synaptic and axonal stability and degeneration in vivo. We therefore used a molecular genetic approach in Drosophila to screen individual proteins for a direct role in neurodegeneration.

We examined the role of individual proteins in regulating synaptic stability and degeneration using the Drosophila olfactory system to screen a collection of existing mutants, or lines with transposon insertions in a subset of these genes. Briefly, mutants and insertion lines were crossed into a background that allowed visualization of a subset of olfactory receptor neurons (ORNs; OR22a-Gal4/UAS-mCD8::GFP). Distal axons and their synaptic fields in the antennal lobe were examined in uninjured controls as well as 7 days after surgical ablation of antennae. Examining uninjured controls allowed us to screen individual mutant lines and test whether they modified basal synaptic and axonal stability (e.g. do synapses and axons degenerate spontaneously in the mutant line?). Spontaneous degeneration was identified by the presence of fragmented axons and absence/decrease of GFP signal in the glomeruli housing synaptic terminals of ORNs [21] and scored using a spontaneous degeneration index, where a score of 0 represented no disruption of axons or synapses in the glomerulus and 5 indicated complete spontaneous breakdown (see methods; Figure 5). Surgical ablation of antennae triggered rapid axonal and synaptic degeneration, which is complete within one day in wild-type controls, and axonal debris is cleared within one week after injury [21]. Screening individual mutant lines 7 days after surgical ablation therefore allowed us to examine whether any of the mutations resulted in a delay in the rate of injury-induced degeneration, scored using a delayed degeneration index where a score of 0 indicated no delay in degeneration and 5 indicated a complete block (see methods; Figure 5).

From our original list of 47 synaptic proteins we obtained Drosophila lines for 21 different genes that harbored either defined mutations known to affect that gene, or P element insertions within the locus identified by the Drosophila Genome Project (see methods). Of the 34 mutant lines obtained, 14 produced viable flies suitable for analyses of axonal and synaptic stability and degeneration (covering a total of 13 individual proteins; Table 1). Eight of the lines examined showed no overt phenotype in either stability or degeneration assays (Table 1). However, 6 mutant lines were found to independently modulate stability or degeneration of distal axons and synapses in ORNs. Mutants of both ALDH1A1 and DNAJC6/Auxillin caused spontaneous degeneration of distal...
axons and synaptic terminals in uninjured ORNs (Figure 5). In
contrast, mutations affecting CALB2/Calretinin, DNAJC5/CSP,
HIBCH and ROCK2 caused a partial delay of injury-induced
degeneration of axons and synapses (Figure 5). In each of these lines,
intact distal axons or axonal fragments were observed 7 days after
experimental nerve lesion, a time-point at which axonal remnants
were never observed in wild-type flies (data not shown [21]).

To provide more robust genetic evidence for a role for one of
these proteins (DNAJC5/CSP) in axonal and synaptic degenera-
tion, we obtained two additional alleles: \( \text{csp}^{X1} \), a loss of function allele which deletes the first exon of \( \text{csp} \); and \( Df(3R)\text{Exel}6138 \), a deletion which completely removes the \( \text{csp} \) locus. Both \( \text{csp}^{X1} \) and \( Df(3R)\text{Exel}6138 \) failed to complement the delay in axonal
degeneration observed with our original allele (\( \text{csp}^{\text{DG29203}} \)), thereby
mapping this phenotype to the \( \text{csp} \) locus (Figure 6). We further note
that the severity of the delay in axonal degeneration appeared to
be enhanced when \( \text{csp}^{\text{DG29203}} \) was placed over either of these null alleles of \( \text{csp} \), which argues that \( \text{csp}^{\text{DG29203}} \) is a weak loss of function allele.

Thus, several individual proteins initially identified as a result of
having modified expression levels in synapse-enriched fractions
undergoing neurodegeneration appear capable of directly influ-
encing synaptic and axonal stability and degeneration in \textit{Drosophila}.
In addition, our work rigorously defines the role of DNAJC5/CSP as an \textit{in vivo}
regulator of synaptic and axonal degeneration.

\textbf{Discussion}

In this study we report on the effective use of a novel ‘top-down’
approach for identifying individual proteins and functional
pathways responsible for regulating neurodegeneration in synaptic
and axonal compartments of neurons. By undertaking a series of
comparative quantitative proteomic screens on degenerating
synapse-enriched fractions isolated from the mouse brain we
identified 47 proteins with robustly modified expression levels
during the early stages of neurodegeneration. We showed that
molecular responses to degeneration occurring in synapse-
enriched fractions following injury were recapitulated in synapse-
enriched fractions undergoing pathological changes as a result of
disease-causing genetic mutations. We also used our proteomic
data to design molecular genetic screens in \textit{Drosophila} that revealed
roles for 6 proteins in regulating synaptic and axonal degeneration

\begin{table}
\centering
\caption{List of viable \textit{Drosophila} lines tested in the current study.}
\begin{tabular}{|l|l|l|}
\hline
Protein & Bloomington ID & Observation \\
\hline
ALDH1 & 12900 & Spontaneous Degeneration \\
Auxillin/DNAJC6 & 26277 & Spontaneous Degeneration \\
CALB2/calretinin & 18382 & Delayed Degeneration \\
CF1 & 7762 & No Overt Phenotype \\
CSP/DNAJC5 & 20497 & Delayed Degeneration \\
DLG1 & 12301 & No Overt Phenotype \\
HIBCH & 30075 & Delayed Degeneration \\
HTT & 24665 & No Overt Phenotype \\
INPP4A & 18046 & No Overt Phenotype \\
NFASC & 5595 & No Overt Phenotype \\
OGDH & 23173 & No Overt Phenotype \\
ROCK2 & 6671 & Delayed Degeneration \\
VPS29 & 13491, 20672 & No Overt Phenotype \\
\hline
\end{tabular}
doi:10.1371/journal.pgen.1002936.t001
\end{table}

In Figure 6, we show representative confocal micrographs
highlighting the injury-induced degeneration of axons and synapses
in wild-type (WT) flies and flies expressing one of the \textit{csp} alleles:
\( \text{csp}^{\text{DG29203}} \). The images demonstrate that expression
of \( \text{csp}^{\text{DG29203}} \) results in a partial delay in the
appearance of axonal and synaptic degeneration, as compared to
flies expressing \( \text{csp}^{\text{DG29203}} \) alone. This effect
was consistent across multiple individual fly lines, demonstrating
that \( \text{csp}^{\text{DG29203}} \) is a weak loss of function allele.

in vivo. These findings further our understanding of mechanisms regulating the active degeneration of synapses and axons, providing a basis from which to develop novel neuroprotective strategies for a range of neurodegenerative conditions.

An initial comparison of the 6 individual proteins found to directly mediate synaptic and axonal stability and degeneration in our Drosophila screen reveals a diverse range of biological functions. For example, both DNAJC5/CSP and DNAJC6 belong to the evolutionarily conserved DNAJ/HSP40 family of proteins that regulate molecular chaperone activity by stimulating ATPase activity [22], whereas CALB2/Ca2+/calmodulin-dependent protein kinase II and ALDH1A1 modulate synaptic transmission with synaptic degeneration [11] (also see below), our findings suggest that endogenous neuronal proteins and pathways regulating synaptic transmission and plasticity [30]. Taken together with previous reports linking perturbations in synaptic transmission with synaptic degeneration [11] (also see below), our findings suggest that endogenous neuronal proteins and pathways regulating synaptic function play an important role in modulating synaptic degeneration. This finding is further reinforced by comparisons of the biological roles of the 6 proteins found to independently regulate degeneration in our Drosophila screen, 5 of which have been implicated in the control of synaptic function: both CALB2/Ca2+/calmodulin-dependent protein kinase II and ALDH1A1 modulate synaptic transmission and plasticity [30]. Taken together with previous reports linking perturbations in synaptic transmission with synaptic degeneration [11] (also see below), our findings suggest that endogenous neuronal proteins and pathways regulating synaptic function play an important role in modulating neurodegenerative pathways.

It is worth noting, however, that at least one of the other proteins found to influence degeneration in our Drosophila screen (HIBCH; 3-hydroxyisobutryl-CoA hydrolase) is unlikely to impact directly on synaptic transmission pathways. HIBCH plays an important role in valine catabolism, disruption of which is sufficient to induce progressive infantile neurodegeneration in humans [31]. Thus, multiple cellular and molecular pathways are likely to converge on mechanisms regulating synaptic and axonal degeneration. This finding is supported by our in vitro analysis revealing that several of the proteins identified in our screen also contribute to pathways regulating neurite development. This supports previous observations from Drosophila models linking ubiquitin-mediated developmental processes with neurodegenerative processes occurring in axonal compartments of neurons [32]. Thus, although proteins and pathways involved in synaptic transmission are likely to contribute significantly to neurodegeneration, other distinct molecular pathways also appear to be capable of influencing synaptic and axonal degeneration in vivo.

Only one of the proteins we identified as a direct mediator of degeneration, DNAJC5/CSP, belongs to the small group of endogenous genes and proteins previously reported to directly affect synaptic stability and degeneration in vivo. DNAJC5/CSP has been implicated in synaptic degeneration contributing to the pathogenesis of neurodegenerative diseases [11,33]. However, our findings are partially inconsistent with previously published studies examining the role of DNAJC5/CSP in animal models. For example, Fernández-Chacón and colleagues reported that loss of CSP expression in mice caused synaptic degeneration in the CNS, leading them to conclude that increased levels of the protein may be neuroprotective [15,34]. By contrast, we found that DNAJC5/CSP levels are robustly and consistently increased in degenerating synapse-enriched fractions following injury and in synapse-enriched fractions from mouse models of neurodegenerative disease. Moreover, a thorough genetic analysis in Drosophila using well-defined mutants in DNAJC5/CSP revealed that loss of CSP is neuroprotective, delaying degeneration in axonal and synaptic compartments. Thus, whilst it is clear that DNAJC5/CSP needs to be regarded as a critical regulator of-neuronal stability and degeneration in vivo, precise details correlating expression levels with its role in stabilizing distal axons and synapses during disease-induced degeneration remain to be determined.

Given that only partial coverage of the entire synaptic proteome is possible through the coupling of subcellular fractionation with current proteomics technologies, alongside the stringent 20% cut-off threshold employed, the refinement methodologies applied in the current study and the limited number of viable fly lines that we screened, it is highly likely that additional genes and proteins capable of regulating neurodegeneration remain to be discovered. Our uncovering of molecular responses underlying neurodegeneration in distal compartments of neurons, alongside the identification of 5 novel mediators of degeneration and new experimental insights into the role of DNAJC5/CSP, suggests that combining proteomic screens on synapse-enriched fractions with axonal/synaptic degeneration assays in Drosophila provides a powerful approach for elucidating mechanisms of neurodegeneration in vivo.

Materials and Methods

Ethics statement

All animal experiments were approved by a University of Edinburgh internal ethics committee and were performed under license by the UK Home Office (project license number 60/3891).

Mouse cortical lesion model

Two month old, female C57Bl/6 (wild-type) and Wild type mice were obtained from Harlan Olac Laboratories (Bicester, UK) and housed within the animal care facilities in Edinburgh. Care was taken to ensure that the wild-type mice did not contain the alpha-synuclein gene deletion that was present in a sub-strain of Harlan Olac B16 mice [18]. All surgical procedures were performed under license from the UK Home Office. General anaesthesia was induced using a mixture of isopentane and oxygen, before securing the head in a Kopf stereotaxic frame. Fur overlying the cranial vault was shaved with scissors before making an incision through the skin at the midline. Four holes were drilled on the left side of skull; 1) in the midline at bregma, 2) in line with the first but at the level of lambda, 3) further caudal on the lateral side just above the temporalis muscle, 4) anterolateral in line with the first and third holes. The skull was cut in lines connecting all holes except the most caudal border, and then reflected. A suction pipette was used to remove all visible cortex under a dissecting microscope, down to the level of the corpus callosum, before replacing the skull-flap [14,19]. The lesion site was filled with gel foam (Ethicon) before replacing the skull-flap. Overlying skin was then sutured and the mouse placed on a heated blanket until recovered fully from the anaesthetic. Mice were maintained in standard animal house conditions and were checked daily for any signs of distress or discomfort as previously described [14,19].

Mouse disease models

R62 mice with a CAG repeat number of 259–266 from breeding colonies at the University of Cambridge were sacrificed at 9–10 weeks old. Mice were genotyped as previously described [20]. Mice lacking BIII-spectrin and age-matched controls from breeding colonies at the University of Edinburgh were raised and...
Preparation of synapse-enriched fractions

Brains were rapidly removed following sacrifice and required brain regions microdissected out (cerebellum from BIH-spectrin mice; striatum from wild-type mice, WldS mice subjected to a cortical lesion and R6/2 mice). Synapse-enriched fractions were prepared as previously described [10]. Briefly, brain regions were homogenised in an ice-cold isotonic sucrose solution (0.32 M sucrose, 1 mM EDTA, 5 mM Tris-HCl, pH 7.4). Homogenate was centrifuged in a fixed-angle rotor at 900 g for 10 min and the supernatant (S1) was collected. The pellet (P1) was resuspended in sucrose solution and centrifuged again at 900 g for 10 min. The resulting supernatant (S1') was combined with S1 and centrifuged in a fixed angle rotor at 20,000 g for 15 min. The supernatant (S2) was discarded and the pellet (P2) containing crude synapse-enriched fractions was washed in a Krebs-like buffer (118.5 mM NaCl, 4.7 mM KCl, 1.18 mM MgCl2, 0.1 mM K2HPO4, 20 mM Hepes, 1.3 mM CaCl2, 10 mM glucose, pH 7.4) then centrifuged at 14,000 g for 10 min.

Quantitative Western blots

Quantitative fluorescent western blotting was performed as previously described [35]. Briefly, protein was extracted (N>3 mice per sample) in RIPA buffer with 10% protease inhibitor cocktail (Sigma). 15–30 µg of protein per lane was separated by SDS/Polyacrylamide gel electrophoresis on 4–20% pre-cast NuPage 4–12% Bis Tris gradient gels (Invitrogen) and then transferred to PVDF membrane overnight. The membranes were then blocked using Odyssey blocking buffer (Li-COR) and then re-suspended in iTRAQ sample buffer (25 mM TEAB, 1 mM DTT, 100 µM iodoacetamide) by vortexing and in this study blots were incubated at room temperature in the dark for 1 hour at room temperature. 100 µl of water was added to each sample to quench the reaction prior to pooling of the six iTRAQ labelled samples and subsequent drying by vacuum centrifugation as previously described [35].

The pooled iTRAQ sample was re-suspended in 50 µl of 25% acetonitrile in 0.1% formic acid prior to loading through a home-made ziptip using 10 µl of 10% slurry of Poros HS in 50:50 methanol:water. The ziptip was then washed with 3 x 25 µl of 25% acetonitrile in 0.1% formic acid prior to loading of the pooled iTRAQ sample. The ziptip was then washed with 3 x 25 µl of 25% acetonitrile in 0.1% formic acid prior to elution with a stepped NaCl gradient in 25% acetonitrile in 0.1% formic acid. A fraction of iTRAQ labelled peptides were then eluted with 2 x 25 µl of 5–800 mM NaCl (5, 10, 20, 50, 100,150, 200, 300, 400, 800) in 25% acetonitrile in 0.1% formic acid. A final elution of the ziptip with 200 mM NH4OH and 50% propanol was used to remove the most hydrophobic peptides. Each fraction was then dried by vacuum centrifugation and stored until mass spectrometry analysis of pooled iTRAQ samples by nano liquid chromatography-mass spectrometry/mass spectrometry (nLC-MS/MS). Prior to this analysis, each dried SCX fraction was re-suspended in 35 ml of 1% formic acid and 10 ml aliquots were injected onto an Agilent 6520 Q-TOF using an Agilent 1200 series nanoLC system with microfluidic interface as previously described [35]. Raw data files were converted to mascot generic file (mgf) by MassHunter workstation software prior to merging of the files with Mascot Daemon and subsequent database (IPI Mouse) searching with the Mascot search engine (Matrix Science, Version 2.2). To be considered as a protein with modified relative expression, the peptide abundance (or average of all peptide abundances for proteins identified by more than one unique peptide) had to be modified by greater than 20% (up or down) [35]. For validation, expression levels of a number of proteins which were identified by a single peptide were quantified in freshly prepared tissue samples using quantitative fluorescent western blotting (see above).

Ingenuity Pathways Analysis (IPA) statistical network analyses were performed as previously described [18].

Drosophila degeneration screen

Drosophila orthologs of the designated mouse proteins were identified, when available, using a reciprocal BLASTing approach and the Ensembl website (ensemble.org). Available mutations were identified in Flybase the following Drosophila mutant stocks were obtained from the Bloomington Stock Center (Bloomington ID #:): 12900, 26277, 18382, 7762, 20497, 12301, 30075, 24665, 18046, 5595, 253173, 6671, 13491, 20672, 25213, 18502, 13446, 13491, 20672, 25213, 18502, 13446, 9109, 11876, 7084, 25107, 7938, 5708, 11734, 29228, 2247, 13491, 139999, 8479, 18884, 23097, 15642, 302, 32035, and 7617. Mutant stocks on the X chromosome were crossed to OR22a-Gal4, UAS-mCD8::GFP flies and males were used for the degeneration screen. Stocks for mutants on the second chromosome were crossed to Sp/Cyo; OR22a-Gal4, UAS-mCD8::GFP, and the progeny were self-crossed to obtain homozygous mutant flies on the second and OR22a-Gal4, UAS-mCD8::GFP on the third chromosome. Similarly, stocks for mutants on the third chromosome were crossed to OR22a-Gal4, UAS-mCD8::GFP; Dr/TM3 and the progeny self-crossed to obtain homozygous mutant flies on the
third chromosome and OR22a-Gal4, UAS-mCD8::GFP on the second chromosome.

The Wallerian degeneration assay was performed as described [21]. Briefly, flies were aged for 7 days after eclosion, to allow strong labeling of ORN axons with GFP. The left 3rd antennal segment was then removed, and the flies aged for another 7 days. The right antennal ORNs served as unlesioned controls. The fly heads were then fixed in 4% formaldehyde/PBS/0.1% Tween, and dissected. Fly brains were mounted in Vectashield and examined by confocal microscopy where they were phenotypically scored by an investigator who was unaware of the genotype. A minimum of 10 animals were examined and assessed per mutant strain.

Spontaneous degeneration in uninjured axons and synapses was scored by eye using the following criteria: 0 = no evidence for fragmentation of axons or loss of GFP fluorescence in the glomerulus; 1 = <10% of axons showing fragmentation and/or mild loss of GFP fluorescence in the glomerulus; 2 = <25% of axons showing fragmentation and/or mild to moderate loss of GFP fluorescence in the glomerulus; 3 = >50% of axons showing fragmentation and/or moderate to severe loss of GFP fluorescence in the glomerulus; 4 = only fragmented axons remaining and/or severe loss of GFP fluorescence in the glomerulus; 5 = no GFP signal remaining in axons or the glomerulus. Delayed degeneration in injured axons and synapses was scored by eye using the following criteria: 0 = no intact axons and no fragments remaining; 1 = no intact axons but fragmented debris remaining; 2 = ~25% of axons intact but with extensive fragmentation of surrounding axons; 3 = ~50% of axons intact with evidence for fragmentation in surrounding axons; 4 = >75% of axons intact with only modest amounts of fragmentation in surrounding axons; 5 = intact axons and synapses with no evidence for fragmentation.

Statistical analysis

Statistical analyses were performed using either Ingenuity Pathways Analysis (IPA) software (for analysis of proteomic data or GraphPad Prism software (for data from quantitative western blots). \( P < 0.05 \) was considered to be statistically significant.

Supporting Information

Table S1 All proteins with altered expression levels >20% in wild-type striatal synaptosome preparations at 24 and/or 48 hrs after cortical lesion. (PDF)

Table S2 All proteins with altered expression levels >20% in Wild\(^{\text{b}}\) striatal synaptosome preparations at 24 and/or 48 hrs after cortical lesion. (PDF)

Table S3 Proteins with altered expression levels >20% in striatal synapse-enriched preparations from wild-type mice 48 hrs after cortical lesion (cpMA = exponentially modified protein abundance index). (PDF)

Table S4 Systems level analysis of functional clustering of proteins modified in degenerating synapses (networks identified as statistically significant clusters \([P < 0.05]\), IPA analysis). (PDF)

Acknowledgments

We thank Simon Parson and members of the Gillingwater, Wishart, and Freeman laboratories for advice and assistance with this research; Sam Eaton for assistance with Western blotting; and Derek Thomson for excellent animal husbandry.

Author Contributions

Conceived and designed the experiments: TMW MRF THG. Performed the experiments: TMW TMR DJL AKW THG. Analyzed the data: TMW TMR MJ. Wrote the paper: TMW MRF THG.

References


